Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Total Liabilities (2016 - 2025)

Regenxbio (RGNX) has 12 years of Total Liabilities data on record, last reported at $350.3 million in Q4 2025.

  • For Q4 2025, Total Liabilities rose 69.77% year-over-year to $350.3 million; the TTM value through Dec 2025 reached $350.3 million, up 69.77%, while the annual FY2025 figure was $350.3 million, 69.77% up from the prior year.
  • Total Liabilities reached $350.3 million in Q4 2025 per RGNX's latest filing, down from $363.8 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $367.3 million in Q2 2025 and bottomed at $206.3 million in Q4 2024.
  • Average Total Liabilities over 5 years is $295.6 million, with a median of $318.5 million recorded in 2022.
  • Peak YoY movement for Total Liabilities: soared 642.14% in 2021, then decreased 21.31% in 2024.
  • A 5-year view of Total Liabilities shows it stood at $349.6 million in 2021, then fell by 9.31% to $317.1 million in 2022, then dropped by 17.3% to $262.2 million in 2023, then fell by 21.31% to $206.3 million in 2024, then soared by 69.77% to $350.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Liabilities were $350.3 million in Q4 2025, $363.8 million in Q3 2025, and $367.3 million in Q2 2025.